] . 34 weeks of gestation-lost in translation. J Obstet Gynaecol Can. 2014;36(6):480-481. 
(706.24 KB)
(706.24 KB). Abnormal liver function tests as predictors of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(10):995-1004. (280.12 KB)
(280.12 KB). Advocacy organisations as partners in pre-eclampsia progress: patient involvement improves outcomes. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):523-36. (438.09 KB)
(438.09 KB). Assessing the incremental value of blood oxygen saturation (SpO(2)) in the miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) Risk Prediction Model. J Obstet Gynaecol Can. 2015;37(1):16-24. (1.11 MB)
(1.11 MB). An assessment of predictive value of the biophysical profile in women with preeclampsia using data from the fullPIERS database. Pregnancy Hypertens. 2013;3(3):166-71. (232.97 KB)
(232.97 KB). Assessment of the fullPIERS Risk Prediction Model in Women With Early-Onset Preeclampsia. Hypertension. 2018;71(4):659-665. (237.99 KB)
(237.99 KB). Assessment, surveillance and prognosis in pre-eclampsia. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):449-62. (178.71 KB)
(178.71 KB). Can adverse maternal and perinatal outcomes be predicted when blood pressure becomes elevated? Secondary analyses from the CHIPS (Control of Hypertension In Pregnancy Study) randomized controlled trial. Acta Obstet Gynecol Scand. 2016;95(7):763-76. (803.67 KB)
(803.67 KB). The Canadian Perinatal Network: a national network focused on threatened preterm birth at 22 to 28 weeks' gestation. J Obstet Gynaecol Can. 2011;33(2):111-120. (322.85 KB)
(322.85 KB). The CHIPS Randomized Controlled Trial (Control of Hypertension in Pregnancy Study): Is Severe Hypertension Just an Elevated Blood Pressure?. Hypertension. 2016;68(5):1153-1159. (476.19 KB)
(476.19 KB). CHIPS-Child: Testing the developmental programming hypothesis in the offspring of the CHIPS trial. Pregnancy Hypertens. 2018;14:15-22. (1011.52 KB)
(1011.52 KB). Community perspectives on the determinants of maternal health in rural southern Mozambique: a qualitative study. Reprod Health. 2016;13(Suppl 2):112. (1019.85 KB)
(1019.85 KB). A comparison of maternal and newborn health services costs in Sindh Pakistan. PLoS One. 2018;13(12):e0208299. (645.08 KB)
(645.08 KB). Control of Hypertension In Pregnancy Study randomised controlled trial-are the results dependent on the choice of labetalol or methyldopa?. BJOG. 2016;123(7):1135-41. (144.71 KB)
(144.71 KB). The Cost Implications of Less Tight Versus Tight Control of Hypertension in Pregnancy (CHIPS Trial). Hypertension. 2016;68(4):1049-55. (470.91 KB)
(470.91 KB). Development and internal validation of a multivariable model to predict perinatal death in pregnancy hypertension. Pregnancy Hypertens. 2015;5(4):315-21. (505.41 KB)
(505.41 KB). Development and internal validation of the multivariable CIPHER (Collaborative Integrated Pregnancy High-dependency Estimate of Risk) clinical risk prediction model. Crit Care. 2018;22(1):278. (961.71 KB)
(961.71 KB). Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can. 2008;30(3 Suppl):S1-S2. (1.73 MB)
(1.73 MB). Diagnostic Performance of Placental Growth Factor in Women With Suspected Preeclampsia Attending Antenatal Facilities in Maputo, Mozambique. Hypertension. 2017;69(3):469-474. (378.99 KB)
(378.99 KB). Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. BJOG. 2016;123(7):1143-51. (153.93 KB)
(153.93 KB). Early diagnosis of preeclampsia using placental growth factor: An operational pilot study in Maputo, Mozambique. Pregnancy Hypertens. 2018;11:26-31. (374.54 KB)
(374.54 KB). Economic evaluation of Community Level Interventions for Pre-eclampsia (CLIP) in South Asian and African countries: a study protocol. Implement Sci. 2015;10:76. (1.88 MB)
(1.88 MB). Effect of magnesium sulphate on fetal heart rate parameters: a systematic review. J Obstet Gynaecol Can. 2014;36(12):1055-1064. (1.57 MB)
(1.57 MB). External Validation of the fullPIERS Model for Predicting Adverse Maternal Outcomes in Pregnancy Hypertension in Low- and Middle-Income Countries. Hypertension. 2017;69(4):705-711. (149.83 KB)
(149.83 KB). Fetal, Infant and Maternal Outcomes among Women with Prolapsed Membranes Admitted before 29 Weeks Gestation. PLoS One. 2016;11(12):e0168285. (862.28 KB)
(862.28 KB). The hypertensive disorders of pregnancy (29.3). Best Pract Res Clin Obstet Gynaecol. 2015;29(5):643-57. (227.04 KB)
(227.04 KB). Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines. PLoS One. 2014;9(12):e113715. (359.44 KB)
(359.44 KB). Improving maternal and perinatal outcomes in the hypertensive disorders of pregnancy: A vision of a community-focused approach. Int J Gynaecol Obstet. 2012;119 Suppl 1:S30-S34. (112.74 KB)
(112.74 KB). The incidence of pregnancy hypertension in India, Pakistan, Mozambique, and Nigeria: A prospective population-level analysis. PLoS Med. 2019;16(4):e1002783. (864.32 KB)
(864.32 KB). Influence of Gestational Age at Initiation of Antihypertensive Therapy: Secondary Analysis of CHIPS Trial Data (Control of Hypertension in Pregnancy Study). Hypertension. 2018;71(6):1170-1177. (303.94 KB)
(303.94 KB). Labetalol for hypertension in pregnancy. Expert Opin Drug Saf. 2015;14(3):453-61. (463.16 KB)
(463.16 KB). Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(24):2367-8. (515.75 KB)
(515.75 KB). Magnesium Sulphate for Eclampsia and Fetal Neuroprotection: A Comparative Analysis of Protocols Across Canadian Tertiary Perinatal Centres. J Obstet Gynaecol Can. 2015;37(11):975-87. (362.1 KB)
(362.1 KB). Magnesium Sulphate for Fetal Neuroprotection. Journal of Obstetrics and Gynaecology Canada. 2011;33(5):516 - 529. (298.54 KB)
(298.54 KB). Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysis. BMC Health Serv Res. 2013;13:527. (2 MB)
(2 MB). Magnesium sulphate for fetal neuroprotection: benefits and challenges of a systematic knowledge translation project in Canada. BMC Pregnancy Childbirth. 2015;15:347. (549.75 KB)
(549.75 KB). MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)-implementation of a national guideline in Canada. Implement Sci. 2018;13(1):8. (1.89 MB)
(1.89 MB). Magnesium sulphate for the management of preeclampsia and eclampsia in low and middle income countries: a systematic review of tested dosing regimens. J Obstet Gynaecol Can. 2014;36(2):154-163. (1.42 MB)
(1.42 MB). Magnocaine: Physical Compatibility and Chemical Stability of Magnesium Sulphate and Lidocaine Hydrochloride in Prefilled Syringes. J Obstet Gynaecol Can. 2016;38(10):936-944.e3. (667.48 KB)
(667.48 KB). Maternal and Newborn Health in Karnataka State, India: The Community Level Interventions for Pre-Eclampsia (CLIP) Trial's Baseline Study Results. PLoS One. 2017;12(1):e0166623. (2.12 MB)
(2.12 MB). Measuring maternal health: focus on maternal morbidity. Bull World Health Organ. 2013;91(10):794-6. (660.26 KB)
(660.26 KB). Moving beyond silos: How do we provide distributed personalized medicine to pregnant women everywhere at scale? Insights from PRE-EMPT. Int J Gynaecol Obstet. 2015;131 Suppl 1:S10-5. (662.6 KB)
(662.6 KB). Multiple Organ Dysfunction Score Is Superior to the Obstetric-Specific Sepsis in Obstetrics Score in Predicting Mortality in Septic Obstetric Patients. Crit Care Med. 2017;45(1):e49-e57. (910.16 KB)
(910.16 KB). Obstetric medical care in Canada. Obstet Med. 2016;9(3):117-9. (81.97 KB)
(81.97 KB). Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG. 2014;121(10):1210-8; discussion 1220. (158.15 KB)
(158.15 KB). Oxygen saturation as a predictor of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Can. 2011;33(7):705-714. (383.37 KB)
(383.37 KB). Performance of the fullPIERS model in predicting adverse maternal outcomes in pre-eclampsia using patient data from the PIERS (Pre-eclampsia Integrated Estimate of RiSk) cohort, collected on admission. BJOG. 2013;120(1):113-8. (85.31 KB)
(85.31 KB). Pharmacotherapy for preeclampsia in low and middle income countries: an analysis of essential medicines lists. J Obstet Gynaecol Can. 2013;35(3):215-223. (529.81 KB)
(529.81 KB). The PIERS experience: research or quality improvement?. J Obstet Gynaecol Can. 2012;34(4):379-81. (233.18 KB)
(233.18 KB). PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can. 2011;33(6):588-597. (292.91 KB)
(292.91 KB)